Taro Pharmaceutical Industries Ltd. (TARO): Price and Financial Metrics

Taro Pharmaceutical Industries Ltd. (TARO): $36.57

-0.49 (-1.32%)

POWR Rating

Component Grades














  • Sentiment is the dimension where TARO ranks best; there it ranks ahead of 94.64% of US stocks.
  • TARO's strongest trending metric is Value; it's been moving down over the last 179 days.
  • TARO's current lowest rank is in the Momentum metric (where it is better than 12.28% of US stocks).

TARO Stock Summary

  • With a price/earnings ratio of 1,515.89, Taro Pharmaceutical Industries Ltd P/E ratio is greater than that of about 99.38% of stocks in our set with positive earnings.
  • Of note is the ratio of Taro Pharmaceutical Industries Ltd's sales and general administrative expense to its total operating expenses; merely 15.4% of US stocks have a lower such ratio.
  • For TARO, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
  • Stocks that are quantitatively similar to TARO, based on their financial statements, market capitalization, and price volatility, are ABCM, FTEK, NLST, TCX, and MELI.
  • Visit TARO's SEC page to see the company's official filings. To visit the company's web site, go to www.taro.com.

TARO Valuation Summary

  • In comparison to the median Healthcare stock, TARO's price/sales ratio is 15.79% higher, now standing at 4.4.
  • TARO's price/earnings ratio has moved up 82 over the prior 243 months.
  • Over the past 243 months, TARO's price/sales ratio has gone up 2.2.

Below are key valuation metrics over time for TARO.

Stock Date P/S P/B P/E EV/EBIT
TARO 2021-08-31 4.4 1.6 87.2 148.4
TARO 2021-08-30 4.4 1.5 86.7 147.2
TARO 2021-08-27 4.5 1.6 87.5 149.1
TARO 2021-08-26 4.5 1.6 89.1 152.7
TARO 2021-08-25 4.6 1.6 90.2 155.2
TARO 2021-08-24 4.5 1.6 88.9 152.2

TARO Growth Metrics

    Its 5 year revenue growth rate is now at -32.18%.
  • The 5 year net income to common stockholders growth rate now stands at -54.85%.
  • Its year over year net income to common stockholders growth rate is now at -258.31%.
TARO's revenue has moved down $384,320,000 over the prior 70 months.

The table below shows TARO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 566.431 -148.901 1.077
2021-09-30 567.592 85.894 7.683
2021-06-30 578.449 25.653 29.498
2021-03-31 548.97 45.77 -386.653
2021-03-31 548.97 45.77 -386.653
2020-12-31 575.562 NA -302.671

TARO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TARO has a Quality Grade of B, ranking ahead of 81% of graded US stocks.
  • TARO's asset turnover comes in at 0.239 -- ranking 182nd of 682 Pharmaceutical Products stocks.
  • ELTP, ADMP, and ENTA are the stocks whose asset turnover ratios are most correlated with TARO.

The table below shows TARO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.239 0.511 -0.005
2021-06-30 0.243 0.535 0.011
2021-03-31 0.231 0.540 -0.326
2021-03-31 0.231 0.540 -0.310
2020-12-31 0.244 0.559 -0.238
2020-09-30 0.249 0.588 -0.202

TARO Stock Price Chart Interactive Chart >

Price chart for TARO

TARO Price/Volume Stats

Current price $36.57 52-week high $74.29
Prev. close $37.06 52-week low $33.58
Day low $36.50 Volume 21,600
Day high $37.53 Avg. volume 25,260
50-day MA $37.47 Dividend yield N/A
200-day MA $48.23 Market Cap 1.37B

Taro Pharmaceutical Industries Ltd. (TARO) Company Bio

Taro Pharmaceutical Industries offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company was founded in 1959 and is based in Haifa Bay, Israel.

TARO Latest News Stream

Event/Time News Detail
Loading, please wait...

TARO Latest Social Stream

Loading social stream, please wait...

View Full TARO Social Stream

Latest TARO News From Around the Web

Below are the latest news stories about Taro Pharmaceutical Industries Ltd that investors may wish to consider to help them evaluate TARO as an investment opportunity.

Taro Completes Acquisition of Alchemee

HAWTHORNE, N.Y., February 28, 2022--Taro Completes Acquisition of Alchemee

Yahoo | February 28, 2022

Taro Pharmaceutical to acquire Alchemee from Galderma

Taro Pharmaceutical Industries (TARO) will acquire Alchemee from Galderma.The deal includes Alchemees business as well as its flagship acne care brand Proactiv.

Seeking Alpha | February 22, 2022

Taro to Acquire Alchemee From Galderma

ZUG, Switzerland & HAWTHORNE, N.Y., February 22, 2022--Galderma and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro") announced today they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company (TPC), from Galderma. The agreement between Galderma and Taro includes Alchemee’s business and assets around the world, including the Proactiv® brand.

Yahoo | February 22, 2022

Taro Pharmaceutical (TARO) Q3 Earnings and Revenues Miss Estimates

Taro (TARO) delivered earnings and revenue surprises of -23.08% and 2.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | January 28, 2022

Taro Provides Results for December 31, 2021


Yahoo | January 27, 2022

Read More 'TARO' Stories Here

TARO Price Returns

1-mo -0.14%
3-mo -16.10%
6-mo -27.02%
1-year -49.18%
3-year -57.76%
5-year -67.37%
YTD -27.02%
2021 -31.75%
2020 -16.50%
2019 3.89%
2018 -19.17%
2017 -0.53%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5032 seconds.